Michael A. Hast - Concepedia

Author

Michael A. Hast

Duke Medical Center

Also Known As

M.A. Hast, Michael A Hast, Michael A. Hast, Michael Hast, Michael A. Hast, Siesser, Priscila F.

Publications

832

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital University of Washington University of South Florida

About

Michael A. Hast is an author at Duke Medical Center specializing in natural sciences, molecular biology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	8	8	400
2	Medicine	7	7	350
3	Biochemistry	6	6	190
4	Microbiology	4	4	125
5	Chemical Biology	2	2	52

Michael A. Hast

Publications

803

Citations

H-Index

Page 1

	Year	Citations
Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination Bridgid E. Hast, Dennis Goldfarb, Kathleen M. Mulvaney, Cancer Research	2013	248
Structures of Human Exonuclease 1 DNA Complexes Suggest a Unified Mechanism for Nuclease Family Jillian Orans, Elizabeth McSweeney, Ravi Iyer, Cell Human Exonuclease 1ChromatinNucleic Acid ChemistryDnaNatural Sciences	2011	160
Structures of Cryptococcus neoformans Protein Farnesyltransferase Reveal Strategies for Developing Inhibitors That Target Fungal Pathogens Michael A. Hast, Connie B. Nichols, Stephanie Armstrong, Journal of Biological Chemistry	2011	61
Phosphorylation of Calcineurin at a Novel Serine-Proline Rich Region Orchestrates Hyphal Growth and Virulence in Aspergillus fumigatus Praveen R. Juvvadi, Christopher Gehrke, Jarrod R. Fortwendel, PLoS Pathogens Fungal Developmental BiologyBiochemistryMicrobial PathogensAspergillus FumigatusFilamentous Fungi	2013	56
Covalent protein–oligonucleotide conjugates by copper-free click reaction Santoshkumar Khatwani, Jun Sung Kang, Daniel G. Mullen, Bioorganic & Medicinal Chemistry Natural SciencesNucleic Acid BiochemistryBioconjugationCovalent Protein–oligonucleotide ConjugatesMolecular Biology	2012	50
Structure-Based Design and Synthesis of Potent, Ethylenediamine-Based, Mammalian Farnesyltransferase Inhibitors as Anticancer Agents Steven Fletcher, Erin P. Keaney, Christopher G. Cummings, Journal of Medicinal Chemistry	2010	48
Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase Michael A. Hast, Steven Fletcher, Christopher G. Cummings, Chemistry & Biology Medicinal ChemistryAnticancer Ethylenediamine InhibitorsDrug TargetBiochemistryProtein Farnesyltransferase	2009	37
Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate Michael A. Hast, L.S. Beese Journal of Biological Chemistry Crystal StructureBioorganic ChemistryAldo-keto ReductaseGlycobiologyMolecular Biology	2008	29
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase Richard T. Eastman, John White, Oliver Hucke, Molecular and Biochemical Parasitology Molecular CharacterizationBiochemistryNatural SciencesMalariaLipid Substrate	2006	28
Caged Protein Prenyltransferase Substrates: Tools for Understanding Protein Prenylation Amanda J. DeGraw, Michael A. Hast, Juhua Xu, Chemical Biology & Drug Design	2008	24

Page 1